James P. Shaffer

This profile gathers the share dealings of James P. Shaffer across 3 companies, led by Eiger BioPharmaceuticals, Inc., Halozyme Therapeutics, Inc. and Clinical Data Inc. We count 21 filings; the first trade dates from 12 April 2011 and the latest from 12 March 2021.

Purchases make up the whole of the open-market record (7 purchases, €172k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 8 share grants and 5 option exercises.

The median purchase comes to €13k. On 1 out of 6 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 15 March 2021, the filings show a share grant in Eiger BioPharmaceuticals, Inc. The clock since the last published purchase (19 August 2016) now reads 3,717 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.